Final results show that approximately 85% of responders with severe alopecia areata maintained substantial hair regrowth through four years on continuous baricitinib therapy. The long-duration maintenance signal provides the clearest durability profile in this dataset among posted outcomes for sustained regrowth. For dermatology stakeholders, the four-year data point improves confidence around long-term benefit persistence, which is essential for treatment planning, discontinuation discussions, and payer decisions. The durability pattern also informs patient counseling on expectations for sustained outcomes and ongoing therapy considerations. As alopecia areata moves increasingly toward chronic disease management frameworks, long-term follow-up endpoints like these can reshape standard-of-care positioning for JAK inhibitors.